Patient demographics
| Characteristic . | N = 21 . |
|---|---|
| Sex, male/female | 9/12 |
| Median age, y (range) | 64 (39-83) |
| Median time from diagnosis, y (range) | 5.9 (2.5-24.2) |
| Median prior therapies, n (range) | 5 (1-8) |
| Prior rituximab, n (%) | 20 (95) |
| Rituximab-refractory, n (%) | 9 (43) |
| Prior ASCT, n (%) | 6 (29) |
| Prior fludarabine, n (%) | 5 (24) |
| Median duration of response to last treatment, mo (range) | 16 (3-112) |
| Baseline hematologic parameters, median (range) | |
| Hemoglobin, g/L | 123 (75-151) |
| Neutrophils, 109/L | 3.27 (1.59-8.28) |
| Platelets, 109/L | 172 (73-325) |
| Characteristic . | N = 21 . |
|---|---|
| Sex, male/female | 9/12 |
| Median age, y (range) | 64 (39-83) |
| Median time from diagnosis, y (range) | 5.9 (2.5-24.2) |
| Median prior therapies, n (range) | 5 (1-8) |
| Prior rituximab, n (%) | 20 (95) |
| Rituximab-refractory, n (%) | 9 (43) |
| Prior ASCT, n (%) | 6 (29) |
| Prior fludarabine, n (%) | 5 (24) |
| Median duration of response to last treatment, mo (range) | 16 (3-112) |
| Baseline hematologic parameters, median (range) | |
| Hemoglobin, g/L | 123 (75-151) |
| Neutrophils, 109/L | 3.27 (1.59-8.28) |
| Platelets, 109/L | 172 (73-325) |
ASCT indicates autologous stem cell transplantation.
Refractory is defined as progression on treatment, stable disease, or partial response or better with progression < 6 months after any prior rituximab-containing therapy.